lamivudine: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
lamivudine: clinical details
Prescribing considerations
- HIV treatment requires combination antiretroviral therapy; lamivudine monotherapy is not appropriate.
- Before hepatitis B treatment, establish HIV status because inadequate lamivudine exposure in unrecognised HIV can select resistance.
- Assess renal function before treatment and after clinically significant changes because lamivudine is mainly renally eliminated.
- In hepatitis B, consider the relatively low genetic barrier to resistance and whether a higher-barrier antiviral is suitable.
- Avoid unplanned withdrawal where hepatitis B is present; arrange post-withdrawal clinical and biochemical follow-up.
Contraindications and cautions
- Hypersensitivity to lamivudine or a formulation excipient.
- The oral solution is unsuitable for people with fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
Monitoring
- For HIV: viral load, treatment response, tolerability and relevant haematological, renal and hepatic parameters.
- For hepatitis B: HBV DNA, liver biochemistry, serological response and evidence of resistance or disease progression.
- Monitor liver function and HBV replication after discontinuation in people with hepatitis B or HIV/HBV coinfection.
- Consider closer viral-load monitoring when chronic use of sorbitol-containing products with oral solution cannot be avoided.
Clinical pharmacology
Lamivudine is phosphorylated intracellularly to lamivudine triphosphate, which terminates viral DNA synthesis. It has limited hepatic metabolism and protein binding and is predominantly excreted unchanged through renal organic-cation transport.
Formulation and product differences
- The selected hepatitis B product is a film-coated tablet licensed for specified adults.
- The selected HIV oral solution is licensed as part of combination therapy for adults and children and includes an oral syringe.
- The HIV oral solution contains sucrose, propylene glycol, sodium and parabens; excipient suitability requires review.
- In children with HIV, tablets are preferred whenever practical because oral solution has produced lower virological suppression and more resistance in comparative data.
- Switching between tablets and oral solution requires formulation-specific prescribing rather than volume-for-tablet substitution.
lamivudine preparations and strengths
Tablet
Route: Oral
Strengths: 100 mg, 150 mg, 300 mg
lamivudine interactions
Tell the specialist or pharmacist about prescribed, over-the-counter and liquid products. Important examples include:
Other lamivudine-containing products
Using more than one risks unintended duplication and should be avoided.
Emtricitabine
It is closely related to lamivudine and should not be taken concurrently.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.